Genfit SA is positioned to bring the second drug to market in non-alcoholic steatohepatitis (NASH) behind Intercept Pharmaceuticals Inc.’s obeticholic acid (OCA), but some analysts have expressed little confidence in Genfit’s elafibranor because of initially poor data in a Phase II trial. New Genfit CEO Pascal Prigent and his team are fighting against that perception as they look forward to reporting data from the Phase III RESOLVE-IT trial early in 2020.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?